Literature DB >> 24696026

Detection of antibodies to the feline leukemia Virus (FeLV) transmembrane protein p15E: an alternative approach for serological FeLV detection based on antibodies to p15E.

Eva Boenzli1, Maik Hadorn2, Sonja Hartnack3, Jon Huder4, Regina Hofmann-Lehmann1, Hans Lutz5.   

Abstract

The aim of this report was to investigate whether the diagnosis of feline leukemia virus (FeLV) infection by serology might be feasible and useful. Among the various viral proteins, the FeLV env-gene product (SU) and the envelope transmembrane protein p15E were considered promising candidates for the serological diagnosis of FeLV infection. Thus, we evaluated p15E and three other FeLV antigens, namely, a recombinant env-gene product, whole FeLV, and a short peptide from the FeLV transmembrane protein, for their potential to detect FeLV infection. To evaluate possible exposure of cats to FeLV, we tested serum and plasma samples from experimentally and naturally infected and vaccinated cats for the presence of antibodies to these antigens by enzyme-linked immunosorbent assays (ELISAs). The serological results were compared with the p27 and proviral real-time PCR results. We found that p15E displayed a diagnostic sensitivity of 95.7% and a specificity of 100% in experimentally infected cats. In naturally infected cats, p15E showed a diagnostic sensitivity of 77.1% and a specificity of 85.6%. Vaccinated cats displayed minimal antibody levels to p15E, suggesting that anti-p15E antibodies indicate infection rather than vaccination. The other antigens turned out to be too unspecific. The lower specificity in cats exposed to FeLV under field conditions may be explained by the fact that some cats become infected and seroconvert in the absence of detectable viral nucleic acids in plasma. We conclude that p15E serology may become a valuable tool for diagnosing FeLV infection; in some cases, it may replace PCR.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24696026      PMCID: PMC4042764          DOI: 10.1128/JCM.02584-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  A VIRUS-LIKE PARTICLE ASSOCIATED WITH LEUKEMIA (LYMPHOSARCOMA).

Authors:  W F JARRETT; E M CRAWFORD; W B MARTIN; F DAVIE
Journal:  Nature       Date:  1964-05-09       Impact factor: 49.962

2.  Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays.

Authors:  Regina Hofmann-Lehmann; Ravi Tandon; Felicitas S Boretti; Marina L Meli; Barbara Willi; Valentino Cattori; Maria A Gomes-Keller; Pete Ossent; Matthew C Golder; J Norman Flynn; Hans Lutz
Journal:  Vaccine       Date:  2005-09-19       Impact factor: 3.641

Review 3.  Feline leukemia virus infection and diseases.

Authors:  E A Hoover; J I Mullins
Journal:  J Am Vet Med Assoc       Date:  1991-11-15       Impact factor: 1.936

4.  Development of the immunofluorescent antibody test for detection of feline leukemia virus infection in cats.

Authors:  W D Hardy; E E Zuckerman
Journal:  J Am Vet Med Assoc       Date:  1991-11-15       Impact factor: 1.936

5.  Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine.

Authors:  R Lehmann; M Franchini; A Aubert; C Wolfensberger; J Cronier; H Lutz
Journal:  J Am Vet Med Assoc       Date:  1991-11-15       Impact factor: 1.936

6.  Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E.

Authors:  Stefan Langhammer; Janine Hübner; Reinhard Kurth; Joachim Denner
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

7.  Evaluation of feline immunodeficiency virus and feline leukemia virus transmembrane peptides for serological diagnosis.

Authors:  J D Fontenot; E A Hoover; J H Elder; R C Montelaro
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

8.  Feline leukemia virus detection by ELISA and PCR in peripheral blood from 68 cats with high, moderate, or low suspicion of having FeLV-related disease.

Authors:  M L Jackson; D M Haines; S M Taylor; V Misra
Journal:  J Vet Diagn Invest       Date:  1996-01       Impact factor: 1.279

9.  Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection among cats in North America and risk factors for seropositivity.

Authors:  Julie K Levy; H Morgan Scott; Jessica L Lachtara; P Cynda Crawford
Journal:  J Am Vet Med Assoc       Date:  2006-02-01       Impact factor: 1.936

10.  Comparative studies of the efficacy of a recombinant feline leukaemia virus vaccine.

Authors:  O Jarrett; J P Ganière
Journal:  Vet Rec       Date:  1996-01-06       Impact factor: 2.695

View more
  9 in total

1.  Retroviral DNA--the silent winner: blood transfusion containing latent feline leukemia provirus causes infection and disease in naïve recipient cats.

Authors:  Stefanie Nesina; A Katrin Helfer-Hungerbuehler; Barbara Riond; Felicitas S Boretti; Barbara Willi; Marina L Meli; Paula Grest; Regina Hofmann-Lehmann
Journal:  Retrovirology       Date:  2015-12-21       Impact factor: 4.602

2.  Putative progressive and abortive feline leukemia virus infection outcomes in captive jaguarundis (Puma yagouaroundi).

Authors:  Claudia Filoni; A Katrin Helfer-Hungerbuehler; José Luiz Catão-Dias; Mara Cristina Marques; Luciana Neves Torres; Manfred Reinacher; Regina Hofmann-Lehmann
Journal:  Virol J       Date:  2017-11-17       Impact factor: 4.099

3.  The Diagnosis of Feline Leukaemia Virus (FeLV) Infection in Owned and Group-Housed Rescue Cats in Australia.

Authors:  Mark Westman; Jacqueline Norris; Richard Malik; Regina Hofmann-Lehmann; Andrea Harvey; Alicia McLuckie; Martine Perkins; Donna Schofield; Alan Marcus; Mike McDonald; Michael Ward; Evelyn Hall; Paul Sheehy; Margaret Hosie
Journal:  Viruses       Date:  2019-05-31       Impact factor: 5.048

4.  Comparative measurement of FeLV load in hemolymphatic tissues of cats with hematologic cytopenias.

Authors:  Mehdi Abdollahi-Pirbazari; Shahram Jamshidi; Seyed Mahdi Nassiri; Mohamad Zamani-Ahmadmahmudi
Journal:  BMC Vet Res       Date:  2019-12-19       Impact factor: 2.741

5.  Anti-SU Antibody Responses in Client-Owned Cats Following Vaccination against Feline Leukaemia Virus with Two Inactivated Whole-Virus Vaccines (Fel-O-Vax® Lv-K and Fel-O-Vax® 5).

Authors:  Mark Westman; Jacqueline Norris; Richard Malik; Regina Hofmann-Lehmann; Yasmin A Parr; Emma Armstrong; Mike McDonald; Evelyn Hall; Paul Sheehy; Margaret J Hosie
Journal:  Viruses       Date:  2021-02-03       Impact factor: 5.048

Review 6.  Vaccination and Antibody Testing in Cats.

Authors:  Herman Egberink; Tadeusz Frymus; Katrin Hartmann; Karin Möstl; Diane D Addie; Sándor Belák; Corine Boucraut-Baralon; Regina Hofmann-Lehmann; Albert Lloret; Fulvio Marsilio; Maria Grazia Pennisi; Séverine Tasker; Etienne Thiry; Uwe Truyen; Margaret J Hosie
Journal:  Viruses       Date:  2022-07-22       Impact factor: 5.818

7.  Detection and Genome Sequencing of SARS-CoV-2 in a Domestic Cat with Respiratory Signs in Switzerland.

Authors:  Julia Klaus; Marina L Meli; Barbara Willi; Sarah Nadeau; Christian Beisel; Tanja Stadler; Herman Egberink; Shan Zhao; Hans Lutz; Barbara Riond; Nina Rösinger; Hanspeter Stalder; Sandra Renzullo; Regina Hofmann-Lehmann
Journal:  Viruses       Date:  2021-03-17       Impact factor: 5.048

8.  Measuring the Humoral Immune Response in Cats Exposed to Feline Leukaemia Virus.

Authors:  Yasmin A Parr; Melissa J Beall; Julie K Levy; Michael McDonald; Natascha T Hamman; Brian J Willett; Margaret J Hosie
Journal:  Viruses       Date:  2021-03-07       Impact factor: 5.048

9.  Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax® FIV).

Authors:  Mark Westman; Dennis Yang; Jennifer Green; Jacqueline Norris; Richard Malik; Yasmin A Parr; Mike McDonald; Margaret J Hosie; Sue VandeWoude; Craig Miller
Journal:  Viruses       Date:  2021-03-12       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.